Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Present at Largest Gathering in Psychedelic Medicine Sector

Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced that its VP of R&D, James Kuo, M.D. M.B.A, will speak as a panelist at Wonderland: Miami, the largest business gathering in the psychedelic medicine sector. According to the update, Silo Pharma is a sponsor of the three-day event slated to take place Nov. 3-5, 2022, in Miami, Florida. Dr. Kuo will speak on the Mainstream Pharma and Psychedelics panel scheduled for Saturday, Nov. 5, on the Science Main Stage. “It will be an honor to join other industry leaders as a panelist at the most influential conference worldwide for the psychedelic medicine industry,” said Dr. Kuo. “As a sponsor of Wonderland, our company looks forward to building awareness for the exciting work we are doing to advance novel new therapies with the power of psychedelic medicine. Our therapeutics target underserved large disease markets like Alzheimer’s disease, multiple sclerosis, and others that stand to benefit greatly from the breakthrough potential of psychedelic drug treatments.”

To view the full press release, visit

About Silo Pharma Inc.

Silo Pharma is a development-stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as PTSD, Alzheimer’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research, which it believes will be transformative to the well-being of patients and the health care industry. For more information about the company, visit

NOTE TO INVESTORS: The latest news and updates relating to SILO are available in the company’s newsroom at

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
404.941.8975 Office
[email protected]

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published:

This entry was posted in Silo Pharma Inc. SILO. Bookmark the permalink.

Comments are closed.